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RetinaPax2 is essential for development of the neural tube, urogenital system, optic vesicle, optic cup and optic
tract. In the eye, Pax2 deﬁciency is associated with coloboma, a loss of astrocytes in the optic nerve and
retina, and abnormal axonal pathﬁnding of the ganglion cell axons at the optic chiasm. Thus, appropriate
expression of Pax2 is essential for astrocyte determination and differentiation. Although BMP7 and SHH have
been shown to regulate Pax2 expression, the molecular mechanism by which this regulation occurs is not
well understood. In this study, we determined that BMP7 and SHH activate Pax2 expression in mouse retinal
astrocyte precursors in vitro. SHH appeared to play a dual role in Pax2 regulation; 1) SHH may regulate BMP7
expression, and 2) the SHH pathway cooperates with the BMP pathway to regulate Pax2 expression. BMP and
SHH pathway members can interact separately or together with TLX, a repressor protein in the tailless
transcription factor family. Here we show that the interaction of both pathways with TLX relieves the
repression of Pax2 expression in mouse retinal astrocytes. Together these data reveal a new mechanism for
the cooperative actions of signaling pathways in astrocyte determination and differentiation and suggest
interactions of regulatory pathways that are applicable to other developmental programs.© 2009 Elsevier Inc. All rights reserved.Introduction
During induction of the eye, the interaction of microenvironmental
cues, signaling pathways, and transcription factors are critical to the
proper patterning of the optic cup, lens, and optic stalk. There are a
large variety of inductive factors, such as retinoic acid, ﬁbroblast
growth factors (FGFs), sonic hedgehog (SHH), WNTs, activins, and
bone morphogenetic proteins (BMPs) that are essential for various
aspects of patterning. In addition, there are a large number of
transcription factors whose expression patterns rely in part on the
presence of these inductive factors (Fuhrmann et al., 2000; Vogel-
Hopker et al., 2000; Zhao et al., 2001). Although the regulation of
transcription factor expression by these factors is partially character-
ized, our understanding of the mechanisms by which these factors
cooperate needs investigation.
One protein that has been identiﬁed as critical to optic cup
development is PAX2, a member of the Paired Box family of
transcription factors. PAX2 plays a pivotal role in eye, ear, spinal
cord and kidney development (Dressler et al., 1990; Eccles et al., 1992;
Nornes et al., 1990). Loss of Pax2 expression has been linked to various
developmental and functional abnormalities such as coloboma (lack306, Center for Regenerative
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l rights reserved.of choroid ﬁssure formation), a marked reduction in optic nerve and
retinal astrocytes, misprojections of the optic nerve, inner ear
malformations, and kidney hypoplasia (Dressler and Douglass,
1992). Interestingly, Pax2 overexpression in the optic cup can
phenocopy the loss of Pax2 expression in some respects, namely the
formation of colobomas, albeit the formation of the colobomas in
gain- and loss-of-function studies appears to be different (Sehgal et
al., 2008). In the vertebrate eye, PAX2 is co-expressed with other
transcription factors like PAX6 and CHX10, throughout the optic
vesicle stage. As development proceeds, inductive factors restrict the
expression patterns of the various transcription factors to lens, retina,
retinal pigmented epithelium (RPE) or optic stalk. At the optic cup
stage, PAX2 is expressed in ventral optic cup and optic stalk and
eventually becomes restricted entirely to the optic stalk, the cells of
which eventually give rise to the astrocytes of the optic nerve (Chu et
al., 2001). A subpopulation of the optic nerve astrocytes then migrate
into the optic cup to generate retinal astrocytes (Chan-Ling and Stone,
1991; Zhang and Stone, 1997).
The BMPs are a large family of secreted proteins that are known to
be critical for the formation of a large array of tissues in the developing
organism (Chen et al., 2004). BMPs can signal through SMAD-
dependent and SMAD-independent pathways (Derynck and Zhang,
2003; Herpin and Cunningham, 2007). In the canonical signaling
pathway, BMP signaling is mediated by the receptor SMADs (R-
SMADs), 1, 5, and 8. Upon activation, these SMADs form a complex
with SMAD4 and the complex is translocated to the nucleus to
430 R. Sehgal et al. / Developmental Biology 332 (2009) 429–443regulate transcription (Dudley and Robertson, 1997). SMADs can
regulate gene expression by binding directly to DNA sequences, or by
interacting with co-activators and co-repressors (Lee et al., 2000;
Miyazono, 1999, 2000a,b; Miyazono et al., 2005; Zhang and Derynck,
2000).
Many of the BMPs are expressed in tissues surrounding the
eyeﬁeld, optic vesicles, and optic cups, and within portions of the eye
itself in the developing and mature organ (Belecky-Adams and Adler,
2001; Dale and Jones, 1999; Hocking and McFarlane, 2007; Koshiba-
Takeuchi et al., 2000; Wilson et al., 2007; Wordinger et al., 2002).
Organogenesis of the eye appears to be reliant on BMPs, in particular
BMP4 and 7 (Adler and Belecky-Adams, 2002; Dudley et al., 1995;
Koshiba-Takeuchi et al., 2000; Sakuta et al., 2001; Trousse et al.,
2001). BMP7 is hypothesized to be critical for many steps in the
progressive development of the eye, including the patterning of the
eyeﬁeld, optic stalk, and optic nerve head, and differentiation of the
retinal pigmented epithelium, lens placode, anterior segment, and
retinal ganglion cells (Adler and Belecky-Adams, 2002; Dale et al.,
1997; Dale and Jones, 1999; Dudley and Robertson, 1997; Furuta et
al., 1997; Hung et al., 2002; Jena et al., 1997; Morcillo et al., 2006;
Muller et al., 2007; Wawersik et al., 1999; Wordinger et al., 2002;
Zhao et al., 2002). At the eye ﬁeld stage, BMP7, is expressed along
with SHH in the prechordal mesoderm underlying the diencephalon
and controls the identity of the rostral diencephalon (Dale et al.,
1997). BMP7 has been shown by several investigators to regulate the
expression of Pax2, although it is unclear whether this regulation is
direct or indirect (Adler and Belecky-Adams, 2002; Dale et al., 1997;
Morcillo et al., 2006).
SHH is a member of the hedgehog family that, much like the BMPs,
appears to be involved in the development of many tissues, including
midline structures, limbs, gastrointestinal tract, and central nervous
system (CNS; Chari and McDonnell, 2007). In vertebrates, the
hedgehog proteins signal through the GLI1, GLI2 and GLI3 transcrip-
tion factors (Hooper and Scott, 2005). How the GLI proteins are
regulated in vertebrates is still not well understood. In both Drosophila
and vertebrates, the SHH binds to the patched homologues (PTC) and
relieves repression on another transmembrane protein, smoothened
(SMO). In Drosophila, active SMO controls the proteolytic processing
of the GLI homologue cubitus interruptus (Ci). Ci is bifunctional; in its
full length form the protein acts as a transcriptional activator, but
following cleavage, the protein will act as a transcriptional repressor
(Parkin and Ingham, 2008). SMO activity regulates the Ci processing
through a complex that includes kinesin protein Cos-2, a serine–
threonine kinase fused, and a novel protein known as suppressor of
fused (Huangfu and Anderson, 2006). The signaling of the SMO
protein and the conservation of pathway members is not clear in
vertebrates, and only one of the GLI proteins, GLI3, has been shown to
be proteolytically cleaved to give rise to the transcriptional repressor
form of the protein (Huangfu and Anderson, 2006). Hence, GLI3 can
function as a functional repressor and activator, while GLI1 and GLI2
are thought to act only as activators (Bai et al., 2004; Motoyama et al.,
2003).
During development, SHH is released from the prechordal
mesoderm to induce the formation of the ﬂoorplate in the midline
neural plate (Dale et al., 1997). The ﬂoorplate itself then expresses
SHH which is proposed to regulate the formation of ventral neural
tube cell fates. The eyeﬁeld, which initially forms in the region
overlying the prechordal mesoderm, is cut into two pieces as the
ﬂoorplate of the neural plate is induced by SHH (Ekker et al., 1995;
Macdonald et al., 1995; Nagase et al., 2005; Ohkubo et al., 2002). At a
molecular level, SHH induces Pax2 expression in this region, which in
turn reciprocally inhibits Pax6. The region that continues to express
Pax2 in the ventral diencephalon becomes the optic stalk. Later in
development, SHH expression is restricted to retinal ganglion cells
and SHH derived from ganglion cell axons is thought to drive the
proliferation of optic nerve astrocytes (Dakubo et al., 2008, 2003;Wallace and Raff, 1999). SHH has also been shown by several
investigators to regulate the expression of Pax2 in the eye (Macdonald
et al., 1995; Schimmenti et al., 2003; Wang et al., 2005). Bovolenta et
al. found that Pax2 is regulated by sequential activity of SHH and
BMP7 (Morcillo et al., 2006). While it is generally accepted that SHH
regulates Pax2 expression, little is known about the mechanism of
Pax2 regulation by these signaling molecules and whether the
regulation is direct or indirect (Macdonald et al., 1995; Morcillo et
al., 2006; Nakamura, 2001).
Pax2 is also regulated in the vertebrate eye by TLX, a member of
the tailless class of orphan nuclear receptors, which has been shown
to repress expression of Pax2 (Yu et al., 2000,1994). In early stages of
development, Tlx is expressed mainly in the dorsal retina with low
levels of expression in the ventral retina, whereas Pax2 expression is
limited primarily to the ventral retina and optic stalk (Nornes et al.,
1990). In the chick optic vesicle, expression of Tlx and Pax2 is
dynamic and transiently overlaps, particularly in the presumptive
optic stalk. Later in development, Tlx is expressed in retinal
progenitor cells and Müller glial cells in the retina. TLX represses
Pax2 by binding to a conserved recognition sequence (AAGTCA) ~80
base pairs upstream of the TATA box (Miyawaki et al., 2004; Yu et al.,
2000).
The studies reported here were directed at understanding the
molecular mechanism by which SHH and BMP7 regulate Pax2
expression in mouse retinal astrocytes. We show that 1) BMP7
expression appears to be regulated by SHH, and 2) SHH and BMP7
interact with TLX on the Pax2 promoter and relieve repression by TLX
in retinal astrocytes.
Results
Phospho-SMAD1 and GLI2 and 3 are present in the developing
optic vesicle, optic stalk, and nerve
Previous reports from our laboratory and others have proposed
that SHH and BMP7 are critical to the development of the optic stalk
astrocytes and have shown that mRNA encoding intracellular
signaling components of the BMP and SHH pathways are present in
the developing optic stalk (Belecky-Adams and Adler, in press;
Dakubo et al., 2003; Furimsky and Wallace, 2006; Morcillo et al.,
2006). Immunohistochemistry was performed to compare the
localization of PAX2 with GLI2, GLI3, and pSMAD1 proteins at
embryonic day 9.5 (E9.5) optic vesicle, E10.5 optic stalk, and E16
optic nerve. As has been described in previous reports (Nornes et al.,
1990), PAX2 was not present in the optic stalk at E9.5 (Figs. 1A–C);
however, GLI2 (Figs. 1D–F), GLI3 (Figs. 1G–I) and pSMAD1 (Figs. 1J–L)
were all present in the optic vesicle at E9.5. GLI2 and phospho-SMAD1
(pSMAD1) were both localized primarily in cells at the ventricular
edge of the optic vesicle, where cells were undergoing mitosis
(compare Figs. 1F and L), while GLI3 immunolabel was present
throughout the optic vesicle (Fig. 1I). Further, GLI3 label was also
present in the presumptive lens ectoderm and in a subpopulation of
mesenchyme surrounding the optic vesicle (Fig. 1I). At E10.5, PAX2
was localized primarily to the ventral optic cup and optic stalk (Figs.
2A–D). GLI2 proteinwas localized to the optic stalk, optic cup and lens
vesicle (Figs. 2E–H). GLI3 was widely expressed throughout the optic
stalk, retinal pigmented epithelium (RPE), optic cup, and lens vesicle
(Figs. 2I–L). Phospho-SMAD1was also localized to the optic stalk, RPE,
optic cup and lens placode (Figs. 2M–P). As was noted at E9.5, GLI2
and pSMAD1immunolabel appeared to be more intense at the
ventricular edge of the dorsal and ventral optic stalk and optic cup,
where dividing cells are located (arrowheads, Figs. 2H and P). In the
E16 eye, PAX2 is restricted to the optic nerve head and optic nerve
(Figs. 3A–C). GLI2 (Figs. 3D–F), GLI3 (Figs. 3G–I), and pSMAD1 (Figs.
3J–L) were all localized to subpopulations of cells in the optic nerve
head (ONH) and optic nerve (ON).
Fig. 1. GLI2, GLI3, and pSMAD1 are expressed in E9.5 optic vesicle prior to PAX2. Ten micrometer cryosections through E9.5 optic vesicle were co-labeled with DAPI and antibodies
against PAX2 (A–C), GLI2 (D–F), GLI3 (G–I), or pSMAD1 (pSMAD1; J–L). Panels A–L show Nomarski and corresponding ﬂuorescent images for DAPI and antibody label. (A–C) PAX2
was not detectable in the optic vesicle at E9.5. (D–F) GLI2-expressing cells were found primarily at the ventricular edge of the optic vesicle (arrowheads, F). (G–I) GLI3 was detected
throughout the optic vesicle (arrowheads, I) and in the presumptive lens placode and a subpopulation of mesenchymal cells. (J–L) Like GLI2, pSMAD1 was detected primarily in cells
lining the ventricular edge of the developing optic vesicle (arrows, L). Magniﬁcation bar in A=50 μm; applies to A–L.
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To begin to unravel the molecular mechanism by which the BMP7
and SHH pathways might regulate the differentiation of retinal
astrocytes, we turned to an in vitro model system which would
allow us to uniformly treat cells with various combinations of the two
growth factors and probe molecular interactions between the two
pathways. We chose to use primary retinal astrocyte precursors
isolated from dissociated retina obtained from 4-week-old transgenic
mice that ubiquitously express a temperature sensitive SV-40 large T
antigen (immorto-mice; Jat et al., 1991). Collagenase-treated cells
were cultured following the depletion of endothelial cells using
antibody-coated magnetic beads (Scheef et al., 2005). Cells were
plated and grown at the permissive temperature of 33 °C and
surviving cells allowed to reach conﬂuence over a 2–3 week period.
Conﬂuent cells were subsequently characterized using immunocyto-chemistry and ﬂuorescence-activated cell sorting (FACs) analyses.
Figs. 4A and B show the morphology of the cells under phase contrast
microscopy. Cells were positive for PAX2 (Fig. 4C), GFAP (Fig. 4D), and
NG2 (Fig. 4E). Consistent with previous analyses of the cells, FACs
analyses indicated that nearly 100% of the cells expressed GFAP and
NG2 (Figs. 4F, G; Scheef et al., 2005). The immunocytochemistry and
FACs analyses coupled with the previous analysis of the cells indicated
that the cells showed characteristics consistent with multipotent
retinal astrocyte precursors (Scheef et al., 2005; Stallcup and Beasley,
1987; Yokoyama et al., 2006).
SHH and BMP7 activate PAX2 and phospho-PAX2
To determine if addition of BMP7 and/or SHH to retinal astrocytes
affected morphology, cells were treated with vehicle, BMP7, SHH, or
BMP7+SHH for 2 days and immunolabeled for PAX2 or GFAP. While
Fig. 2. Expression of PAX2, GLI2, GLI3, and pSMAD1 in E10.5 optic cup. Ten micrometer cryosections through E10.5 optic cup were co-labeled with DAPI and antibodies against PAX2
(A–D), GLI2 (E–H), GLI3 (I–L), or pSMAD1 (M–P). Panels (A–T) showNomarski and corresponding ﬂuorescent images for DAPI and antibody label. (A–D) As shown by arrowheads in
D, PAX2 was localized to the ventral optic cup and optic stalk at E10.5. (E–H) Similar to localization at E9.5, stronger GLI2 signals were found at the ventricular edge of the optic stalk
(arrowheads, H), and weaker signals were detected throughout the rest of the optic stalk, optic cup, and lens. (I–L) GLI3 was found throughout the optic stalk, retinal pigmented
epithelium, and the lens placode. (M–P). Phospho-SMAD1 localization was similar to that noted for GLI2, with higher signal detected in cells at the ventricular edge (arrowheads, P)
and weaker signals noted throughout the rest of the optic stalk, optic cup, and lens. (Q–T) Negative controls inwhich primary antibody was omitted show no background label in the
optic stalk, optic cup, and lens. Magniﬁcation bar in A=50 μmand applies to photomicrographs in A–C, E–G, I–K, M–O, and Q–S. Bar in D=50 μmand applies to photomicrographs in
D, H, L, P, and T. Abbreviations: DOS; dorsal optic stalk, VOS; ventral optic stalk, RPE; retinal pigmented epithelium, R; retina, LP; lens placode, L, lens.
432 R. Sehgal et al. / Developmental Biology 332 (2009) 429–443there were no detectable changes in appearance or number (data
not shown) of the cells, there were evident increases in the amount
of PAX2 immunoﬂuorescence of treated cells in comparison to the
control vehicle-treated cells (Fig. 5A). To verify the increase in levelsof PAX2, lysates of treated cells were subjected to western analysis.
Cells were treated with vehicle, BMP7, SHH, or both BMP7 and SHH
for 4 h, cell lysates separated by SDS-PAGE, and immunoblot for
PAX2 performed. As shown in Fig. 5B, there was a notable increase
Fig. 3. Expression of PAX2, GLI2, GLI3, and pSMAD1 in E16 optic nerve. Ten micrometer cryosections through E16 optic nerve head and nerve were co-labeled with DAPI and
antibodies against PAX2 (A–C), GLI2 (D–F), GLI3 (G–I), or pSMAD1 (J–L). Panels (A–O) show Nomarski and corresponding ﬂuorescent images for DAPI and antibody label. (A–C)
PAX2 was detected in nuclei of the optic nerve head (ONH) and optic nerve (ON) at E16 (arrowheads, B and C). GLI2 (arrowheads E and F), GLI3 (arrows, H and I) and pSMAD1
(arrowheads, K and L) were also detected in the nuclei of cells in the ONH and ON. Negative controls inwhich the primary antibody was omitted are shown inM–O. Magniﬁcation bar
in A=50 μm and applies to photomicrographs in A–O. Abbreviations: RPE, retinal pigmented epithelium; ON, optic nerve; ONH, optic nerve head; R, retina.
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to the vehicle control (Fig. 5B). These assays showed the 46 and
48 kDa forms seen in previous studies (Dressler and Douglass, 1992)
also were present in these cells (Fig. 5B). Densitometric analysis
revealed a 3-fold increase in PAX2 protein in lysates treated with
BMP7 or SHH and a 4-fold increase in lysates co-treated with BMP7
and SHH compared to control cultures treated with vehicle alone
(Fig. 5B’).PAX2 activity is regulated by phosphorylation of a carboxyl-
terminal trans-activation domain that is rich in serine and threonine
residues (Cai et al., 2002). To determine if there was a concomitant
increase in phospho-PAX2 following treatment of retinal astrocytes
with BMP7, SHH, or both, western blotting of lysates from treated cells
was performed using a phospho-PAX2 speciﬁc antibody. Immunoblots
showed 1.6-fold and 2-fold increases in phospho-PAX2 levels in
lysates treated with BMP7 or SHH, respectively, in comparison to
Fig. 4. Characterization of mouse retinal astrocyte precursors. (A, B) Phase photomicrographs of isolated cells grown in culture for 3 weeks at low (A) and higher magniﬁcation (B).
(C, D) Immunocytochemistry was performed on cells using antibodies against optic nerve and retinal astrocyte markers PAX2 (C), glial ﬁbrillary acidic protein (GFAP; D), and NG2
proteoglycan (E). (F, G) FACs analysis of cells for GFAP (F) and NG2 (G) expression indicated that nearly 100% of the cells were positive for GFAP and NG2. The shaded graphs in both E
and F show staining with control IgG. Magniﬁcation bar in A=40 μm. The bar in B=100 μm and applies to photomicrographs in B–D.
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showed an approximately 3-fold increase over controls (Figs. 5C, C’).
Cells treated with SHH have increased levels of phospho-SMAD1
Because the observed increases in both PAX2 and phospho-PAX2 in
the cells treated with BMP7 and SHH were sub-additive, the
possibility of cross talk between the two signaling pathways was
investigated. Retinal astrocytes were treated with control vehicle,
BMP7, SHH, or both BMP7 and SHH and lysates of cells were assayed
for the downstream signaling component of the canonical BMP
pathway, pSMAD1. Vehicle-treated cells showed a basal level ofpSMAD1 (Fig. 6A). As expected, BMP7-treated cells showed an
increase in the levels of pSMAD1. Interestingly, there was also an
increase in pSMAD1 following SHH treatment, and co-treatment
yielded a sub-additive increase in pSMAD1 similar to what had been
seen in previous experiments in which BMP7 and SHH were added to
the cultures.
A densitometric analysis of the western blot using β-tubulin as a
loading control showed a 2-fold increase in pSMAD1 levels in BMP7-
treated, a 2.7-fold increase in SHH-treated and a 3-fold increase in co-
treated cells over vehicle (Figs. 6A, A’). As a negative control the same
blot was subjected to an antibody speciﬁc for phospho-SMAD2, the
downstream signaling component of activin and other TGFβ growth
Fig. 5. SHH and BMP7 promote increased levels of PAX2 and phospho-PAX2 in retinal astrocytes. (A) Expression of PAX2 (a–d) and GFAP (e–h) in retinal astrocytes treated with
control vehicle (a, e), BMP7 (b,f), SHH (c, g) and BMP7+SHH (d, h). Digital photomicrographs were taken at the same exposure and are unprocessed. Note the increase in PAX2
immunoreactivity of treated cells (b, c, d) in comparison to vehicle-treated cells (a). (B) PAX2 levels were measured by western blotting after treatment of retinal astrocytes with
BMP7, SHH, or BMP7 and SHH (n=3). Note the increase in the amount of PAX2 in isolates of treated cells in comparison to control. (B’) Densitometric analysis of experiments shown
in B normalized to the β-tubulin loading control. Values shown above histogram bars indicate the level of statistical signiﬁcance for each treatment in comparison to controls. (C)
Phospho-PAX2 levels were assayed by western blotting in astrocytes treated with BMP7, SHH, or BMP7 and SHH (n=3). (C’) Densitometric analysis of immunoblot shown in C
normalized to β-tubulin. Values shown above histogram bars indicate the level of statistical signiﬁcance for each treatment in comparison to controls. Magniﬁcation bar in a=50 μm
and applies to photomicrographs in a–h.
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phospho-SMAD2 following treatment of cells in comparison to the
vehicle controls (Figs. 6B, B’).
Follistatin abolishes the increase in phospho-SMAD1 protein in
SHH-treated cells
The previous result suggested that the SHH pathway was
regulating pSMAD1 levels, either through pathway cross talk or by
regulating expression of one or more members of BMP pathway. If
SHH regulates BMP7 expression, we hypothesized that treatment of
cells with a BMP7 inhibitor should abolish the effects of both BMP7
and SHH on pSMAD1 levels. To block BMP signaling, we treated cells
with each growth factor separately or in combination with follistatin
and a BMP7 function-blocking antibody. Cell lysates were analyzed for
levels of pSMAD1. Consistent with our prior observations, treatment of
the cells with BMP7, SHH or both factors yielded an increase in
pSMAD1 that was greater in the lysates from control-treated cells (Fig.6D). As would be expected if SHH signaling were regulating BMP
expression, co-treatment with follistatin and BMP7 function-blocking
antibody blocked pSMAD1 signaling following treatment with each
factor alone or in combination. A densitometric analysis of the blots
using α-tubulin as a loading control showed a 2-fold increase in
lysates treated with BMP7, a 2.5-fold increase in SHH-treated lysates
and a 3.3-fold increase in lysates co-treated with BMP7 and SHH.
Lysates treated with growth factors and combination of follistatin and
BMP7 function-blocking serum showed N10-fold decrease in levels of
pSMAD1 (Figs. 6D, D’).
Cyclopamine treatment decreases BMP7 protein levels in vitro
To further test if BMP7 expression is regulated by SHH, cells were
treated with vehicle or cyclopamine (an inhibitor of SHH signaling),
and analyzed for levels of BMP7 by western blotting. BMP7 protein
levels in cyclopamine treated cells were decreased as compared to the
vehicle-treated cells. Densitometric analysis showed a 2-fold decrease
Fig. 6. Cells incubated with SHH have increased levels of phospho-SMAD1. (A–C) Western analysis of retinal astrocytes treated with BMP7, SHH, or BMP7 and SHH for pSMAD1 (p-
SMAD1; A) or phospho-SMAD2 (p-SMAD2; B). (A’) Densitometric analysis of experiments shown in A normalized to the β-tubulin loading control (C; n=3). (B’) Densitometric
analysis of experiments shown in B normalized to the β-tubulin loading control (n=3). Open triangles indicate a lack of a statistically signiﬁcant effect of BMP7, SHH or BMP7 and
SHH on phospho-SMAD2 protein levels in comparison to control vehicle-treated cells. (D) Western analysis of experiments in which SHH, BMP-7 and co-treated retinal astrocytes
were cultured in the presence or absence of follistatin and BMP7 function-blocking antibody. Immunoblots of lysates were incubated with pSMAD1 and loading control α-tubulin
(n=3). (D’) Densitometric analysis of experiments shown in D normalized to α-tubulin. Values shown above histogram bars indicate the level of statistical signiﬁcance for each
treatment in comparison to controls. (E) Western analysis of lysates from retinal astrocytes treated with vehicle or cyclopamine and analyzed for BMP7 expression (n=3). (E’)
Densitometric analysis of experiments depicted in E normalized to β-tubulin. The asterisk indicates statistical signiﬁcance of BMP levels as compared to vehicle-treated cells.
436 R. Sehgal et al. / Developmental Biology 332 (2009) 429–443in BMP7 protein levels in cyclopamine treated cells compared to
vehicle controls (Figs. 6E, E’).
BMP7 and SHH decrease the binding of TLX protein on Pax2 promoter
Tailless (TLX) is an orphan nuclear receptor that acts as a
suppressor of Pax2 expression and is essential for eye development
(Yu et al., 2000). We hypothesized that TLX repression would have to
be removed to allow Pax2 expression and induction of astrocyte fate in
the optic stalk. To begin to examinewhether the intracellular signalingpathways activated by BMP7 and SHH decreased TLX availability to
interact with the proximal Pax2 promoter sequences, we performed
EMSA reactions using nuclear extracts of treated astrocytes and
biotin-labeled oligonucleotides containing the TLX-binding site in the
Pax2 promoter. If the BMP and/or SHH pathways interfered with TLX
repression, then one might expect to see a decrease in TLX binding to
its consensus sequences in the presence of nuclear extracts from
treated cells. As was hypothesized, TLX-binding activity for the Pax2
promoter sequence was decreased in cells treated with both BMP7
and SHH (Figs. 7A, C; n=4). Parallel EMSA reactions using in vitro
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astrocytes (Fig. 7B, lane 3) served as controls for TLX protein/DNA
complex migration (Fig. 7B). Further, treatment of EMSA reactions
containing nuclear extracts from astrocytes incubated with the oligo
representing the TLX-binding site followed by incubation with an
antibody speciﬁc for TLX showed a supershift of the detected band
conﬁrming the presence of TLX in the complex (Fig. 7B, lane 4).
To conﬁrm that there was indeed less TLX bound to the TLX
consensus site of the Pax2promoter, a chromatin immunoprecipitation
(ChIP) using TLX antibody was performed using lysates from retinal
astrocytes treated with vehicle, BMP7, SHH, or BMP7+SHH. Quanti-
tative PCR (qPCR)was done using primers speciﬁc for a 60 bp region of
the Pax2 promoter encompassing the TLX-binding region of the Pax2
promoter (Fig. 7D). Comparable to the EMSA analysis, treatment of
cells with BMP7, SHH, or BMP7+SHH decreased the amount of Pax2
ampliﬁed, indicating that less TLX was immunoprecipitated as a
complex with the Pax2 promoter in treated cells (Fig. 7D).
TLX, GLI2 and pSMAD1 interact with each other
There are several ways which the SHH and BMP pathways might
decrease TLX binding to its consensus site. For instance, the SMADs
and/or GLIs might 1) bind to TLX to keep it from binding to DNA or
release it from the consensus site, or 2) bind to DNA and sterically
interfere with TLX binding to its consensus sequences. To analyze
whether decreased binding of TLX following BMP7 and SHH signaling
involves interaction of their downstream components pSMAD1 and
GLI2 respectively, co-immunoprecipitation (Co-Ip) was performed.
Retinal astrocytes were treated with vehicle and total proteins were
isolated. Extracted nuclear proteins from treated cells were precipi-
tated with control β-tubulin, GLI2 or pSMAD1 antibodies and then
blotted with antibody speciﬁc to TLX (Fig. 7E; a), pSMAD1 (Fig. 7E; b)
or GLI2 (Fig. 7E; c). As expected, lysates incubated with control β-
tubulin antibody do not co-precipitate TLX, GLI2, or pSMAD1 (Fig. 7E;
ﬁrst lane). All of the proteins were detected following immunopre-
cipitation using the pSMAD1 or GLI2 antibodies, consistent with the
hypothesis that these proteins interact with each other (n=3). To
determine if TLX, GLI2 and/or pSMAD1 could also form complexes in
treated cells, Co-Ips were performed using nuclear extracts from cells
treated with BMP7, SHH, or BMP7+SHH (n=3). As was seen in
vehicle-treated cells, TLX, GLI2, and pSMAD1 were immunoprecipi-
tated as a complex when cells were incubated with pSMAD1 or GLI2
antibody (data not shown).
An alternate hypothesis would be that BMP7 and SHH treatment of
astrocytes downregulates the expression of TLX. To rule out BMP7 or
SHH regulation of TLX expression, western blotting was performed on
BMP7, SHH, and co-treated cells. No signiﬁcant differences in amounts
of TLX proteinwere apparent in the treated cells compared to controls
(Figs. 7F, F’).
To test whether SMAD1 or GLI2 could bind to sequences within the
proximal promoter of Pax2 and thereby sterically hinder TLX binding,
we performed an avidin–biotin complex DNA-binding (ABCD) assay.
This assay is used to evaluate the interactions of endogenous proteins
(SMAD1 and GLI2) with the biotinylated double-stranded DNA
oligonucleotides containing the binding element of interest. Total
cellular proteins from retinal astrocytes were isolated and incubated
with biotin-labeled oligonucleotides representing the TLX-binding
site in the Pax2 promoter. Proteins bound to the TLX-binding site
oligonucleotides were puriﬁed by streptavidin–agarose chromatogra-
phy, eluted from the beads, separated on SDS-PAGE gels, transferred
and blotted with antibody speciﬁc for TLX, pSMAD1, or GLI2.
Consistent with our other observations, TLX protein was observed to
bind to the TLX-binding site (Fig. 7G). Interestingly, neither pSMAD1
or GLI2 could be detected, although control experiments showed that
pSMAD1 and GLI2 were detectable in assays using the consensus
SMAD or GLI sites respectively (data not shown).SHH and BMP7 regulate Pax2 promoter activity in the presence of TLX
To determine if SHH and BMP7 can regulate the activity of the Pax2
promoter within retinal astrocytes, luciferase assays were performed.
Astrocytes were transiently co-transfected with an expression vector
for TLX (CMV-TLX) and a luciferase reporter gene containing 900 bp of
the proximal Pax2 upstream region (Pax2-Luc). Cells were incubated
with vehicle or growth factors for 24 h, lysed, and total proteins were
analyzed for luciferase activity. As expected, cells co-transfected with
CMV-TLX and Pax2-Luc vectors showed decreased levels of luciferase
activity in comparison to those transfected with Pax2-Luc plus control
expression vector (Fig. 8A). Cells transfected with Pax2-Luc and
subsequently treated with either BMP7 and/or SHH showed at least a
2-fold increase in luciferase activity. Consistent with our hypothesis,
cells co-transfected with CMV-TLX and Pax2-Luc and treated with
either BMP7, SHH or BMP7 and SHH were able to relieve Pax2
repression to varying degrees (Fig. 8A).
P-SMAD1 and GLI2 decrease TLX-binding at the Pax2 proximal promoter
To verify that pSMAD1 and GLI2 are found at the Pax2 promoter in
situ, cells were treated with vehicle or BMP7+SHH and a ChIP
analysis performed on the lysates using antibodies speciﬁc for
pSMAD1, GLI2, or TLX. The results of the ChIP were then analyzed
by qPCR using primers that ampliﬁed the proximal Pax2 promoter
(Fig. 8B). As was seen in the previous ChIP analysis, TLX appeared to be
abundant at the Pax2 promoter in vehicle-treated cells. However, in
lysates from treated cells there was a decrease in Pax2 ampliﬁcation of
approximately 2-fold. Furthermore, treated cells showed a dramatic
increase in the levels of ampliﬁed Pax2 when pSMAD1 and GLI2 were
used for the ChIP analysis. Together these results support the
hypothesis that untreated retinal astrocyte precursors have high
levels of TLX bound to the Pax2 promoter, while cells treated with
BMP7 and/or SHH have relieved TLX repression of Pax2 expression by
removal of TLX and a concomitant increase in pSMAD1 and GLI2
bound to the proximal Pax2 promoter.
Discussion
The present study focuses on the mechanism of regulation of Pax2
by SHH and BMP7. Indirect immunohistochemistry showed that
critical members of the BMP and SHH pathways were present in the
optic vesicle just prior to Pax2 expression and were present in the
PAX2-expressing optic stalk and optic nerve. Primary cultures of
retinal astrocytes were used to probe the interactions of the two
pathways in retinal astrocytes. Cells were treated with BMP7 and SHH
and the results analyzed by western blotting, electrophoretic mobility
shift assay, ABCD assay, co-immunoprecipitation, luciferase assays,
and ChIP-qPCR. The following conclusions could be drawn from these
experiments; 1) BMP7 and SHH increase PAX2 and phospho-PAX2
levels in astrocytes, 2) SHH regulates BMP7 expression in astrocytes,
3) SHH and BMP7 relieve Pax2 repression by decreasing the binding of
TLX, and 4) the modulation of TLX repression of Pax2 expression is
likely to include binding of both pSMAD1 and GLI2 to TLX, rather than
regulation of TLX mRNA or protein levels or steric interference of TLX
binding to the Pax2 promoter.
Cooperation of SHH and BMP pathways
Although the SHH and BMP pathways are typically described as
having antagonistic effects in patterning of the central nervous
system, our results, as well as the results of other labs, indicate that
this may be a simplistic model (Arkell and Beddington, 1997; Liem et
al., 1995). An excellent example of this is the interactions of BMPs and
SHH in the neural tube. BMPs have been proposed as one of the
“dorsalizing” factors, along with wnts and activins, whereas SHH has
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and Briscoe, 2007). What is rarely acknowledged is the fact that some
of the BMPs (as well as certain wnts) are also expressed in the
prechordal mesoderm underlying the forebrain andmidline portion of
the neural tube (Dale et al., 1997; Furuta et al., 1997; Placzek and
Briscoe, 2005). Dale et al. (1997) have shown that both BMP7 and SHH
are co-expressed in the prechordal mesoderm and are required to
induce the formation of ventral midline cells of the rostral
diencephalon. BMP7 reportedly acts on the midline neural cells tomodify their response to SHH, inducing the expression of markers
found only in rostral diencephalon (Dale et al., 1997). Interestingly,
studies by Morcillo et al. (2006) have also suggested that the activity
of BMP7 and SHH are necessary for the proper patterning of the optic
nerve head and optic ﬁssure and that the activity of BMP7 prior to SHH
signaling is necessary for Pax2 expressing cells in the optic nerve head.
These ﬁndings are not restricted to the optic nerve and Pax2.
Investigations in other tissues also suggest that SHH and BMPs can act
cooperatively (Suzuki et al., 2004; Yuasa et al., 2002). The cooperation
Fig. 8. SMADs and GLIs regulate the Pax2 promoter in astrocytes and are present at the
Pax2 promoter. A) Retinal astrocytes were co-transfectedwith 300 ng of Pax2-Luciferase
(Pax2-Luc) and 200 ng of either CMV-TLX or empty CMV vectors and then treated with
vehicle, BMP7, SHH or BMP7 and SHH, 24 h following the transfections. Cells were lysed
and total proteins were analyzed for the luciferase activity. The luciferase activity was
normalized to the total proteins in each condition. Cells co-transfected with Pax2-Luc
and empty CMV vectors treated with vehicle, show basal level of luciferase activity
whereas cells co-transfected with Pax2-Luc and CMV-TLX vectors and vehicle treated
after 24 h, show signiﬁcant reduction in luciferase activity. Similarly, Pax2-Luc
transfected astrocytes treated with BMP7, SHH and BMP7 and SHH show marked
reduction in the Pax2 reporter gene activity in the presence of CMV-TLX transfected
vector as compared to the empty CMV vector where the treated cells show signiﬁcantly
greater reporter gene activity than the vehicle-treated control cells. Transfections were
done in triplicate in 3 different experiments using different DNA preps for each
experiment. Statistical signiﬁcance is reported above the graph. B) Chromatin
immunoprecipitation (ChIP) using TLX, pSMAD1, and GLI2 antibodies followed by
qPCR for Pax2. Retinal astrocytes were treated with vehicle or BMP7+SHH and
chromatin/protein complexes immunoprecipitated with antibodies speciﬁc for phos-
pho-histone 3 (bar 1), TLX (bars 2 and 3), pSMAD1 (bars 4 and 5), GLI2 (bars 6 and 7), or
pSMAD1 and GLI2 (bars 8 and 9). Binding of the proteins to the TLX site in the proximal
region of the Pax2 promoter was examined using Taqman qPCR. As a positive control,
antibody against acetyl-Histone H3was used to precipitate protein/DNA complexes and
primers for GAPDHused for ampliﬁcation (ﬁrst bar). The values for the acetyl-histoneH3
were automatically set to a value of 1. GAPDH was used as an internal control for all
experiments and values shown in B are normalized to GAPDH. Values for the rabbit IgG
negative control were subtracted from experimental values prior to plotting.
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First, SHH and BMPs have been shown by various investigators to
regulate each other's expression (Kawai and Sugiura, 2001; Zhang et
al., 2000), although the level of BMPs present appeared to determine
whether the SHH expression is upregulated or inhibited (Zhang et al.,
2000). That BMPs may regulate the expression of SHH is consistent
with the idea that BMP7 and SHH sequentially regulate patterning andFig. 7. BMP7 and SHH decrease the binding of TLX protein on Pax2 promoter. (A) Electrophore
treated with vehicle, BMP7, SHH, or BMP+SHH (n=4). Biotinylated oligonucleotide repres
used to probe nuclear extracts. Note the decrease in TLX bound in cells co-treated with BMP
with labeled oligo representing the TLX-binding site in the Pax2 promoter (lane 2), nuclear
nuclear extracts from untreated retinal astrocytes was incubated with labeled oligo in the pr
TLX antibody. No shift or supershift was detected in samples incubated without labeled oligo
histogram bars indicate the statistical signiﬁcance of each treatment in comparison to control
immunoprecipitation (ChIP) assay using extracts from retinal astrocytes treated with vehicle
complexes and primers to the TLX-binding site within the Pax2 promoter used to amplify w
precipitate protein/DNA complexes and primers for Glyceraldehyde-3-phosphate (GAPDH) u
set to a value of 1. GAPDH was used as an internal control for all experiments and values s
subtracted from experimental values prior to plotting. Compare the decrease in the amoun
amount of TLX bound in EMSAs (C). (E) Co-immunoprecipitation (Co-Ip) was performed b
(lane 2) or GLI2 (lane 3) and analyzed by western blotting for TLX (a), pSMAD1 (b), or GLI2
(b) Lane 2 acts as a positive control to show that pSMAD1 was immunoprecipitated by pSMA
conﬁrms the interaction of GLI2 with pSMAD1. Lane 3 acts as a positive control. (F) TLX pro
experiments were all performed a total of 3 times. (F’) Densitometric analysis of experiment
biotin complex DNA binding assay (ABCD assay) was used to determine if pSMAD1 or GLI2 we
TLX-binding site in the proximal Pax2 promoter was incubated with nuclear lysates from un
probe (lane 1). TLX was the only protein detected when the TLX-binding site was present (differentiation in the diencephalon (Dale et al., 1997; Morcillo et al.,
2006). A second mechanism by which SHH and BMPs may act
coordinately may be crosstalk of the pathways with one another. For
instance, there is evidence that the BMP pathways interact with the
notch, Toll, and MAP kinase pathways (reviewed in Herpin and
Cunningham, 2007). Finally, the last way in which the BMP and SHH
pathways might act coordinately is through co-regulation of genes.
The SMADs have been shown to regulate gene expression either by
binding to DNA directly with co-activators or co-repressors, or by
binding to other transcription factors to regulate their binding to DNA
(Miyazono et al., 2005). There are at least 3 consensus DNA
recognition sequences for the BMP-activated SMADs (Kim et al.,
1997; Kusanagi et al., 2000; Shim et al., 2002). The SMADs have also
been shown to interact with many different transcription factors,
although only a handful of factors have been implicated in binding to
the BMP-related SMADs, including Runx, Menin, YY1, Msx1, Vent2,
MyoD, Hoxc8, SIP1, FoxG1, p300, CBP, cSki, SnoN, and GCN5 (Miyazono
et al., 2005). This is one of the ﬁrst studies to show that BMP and SHH
pathways may interact with each other to regulate gene expression.
TLX and Pax2 regulation
TLX is an orphan nuclear receptor that plays an important role in
regulating cell numbers and astrocyte development in the developing
retina (Miyawaki et al., 2004). TLX is also implicated in forebrain
development and emotional behavior (Roy et al., 2002). TLX regulates
Pax2 by binding the promoter at a recognition sequence which has
been conserved in mouse and humans (Yu et al., 2000). In addition,
TLX is expressed in proangiogenic astrocytes and its expression is
controlled by oxygen concentration. TLX acts as a proangiogenic
switch which becomes active in low concentrations of oxygen. After
retinal angiogenesis, TLX is downregulated and its angiogenic activity
is switched off when astrocytes come in contact with the blood vessels
(Uemura et al., 2006). BMPs also are expressed in endothelial cells as
well as playing key roles to regulate the developmental program of
hematopoietic cells in humans (Bhatia et al., 1999; Fan et al., 2002). In
this study, BMP7 and SHH were shown to relieve the repression of
Pax2 by TLX by interacting with TLX. Astrocyte migration into the
retina precedes the formation of blood vessels (Fruttiger, 2007; Stone
and Dreher, 1987). PAX2 (+) perinatal astrocytes closely associate
with blood vessels (Chu et al., 2001). In addition, after completion of
blood vessel formation, astrocytes lose their proangiogenic properties
but continue to maintain vascular homeostasis by promoting the
formation and maintenance of blood–retina barrier (Abbott, 2002;
Gardner et al., 1997; Janzer and Raff, 1987). We hypothesize that after
hypoxia-induced blood vessel formation occurs, TLX repression of
Pax2 is relieved by BMPs from the blood and then Pax2 continues its
expression in astrocytes.tic mobility shift assay (EMSA) performed using nuclear extracts from retinal astrocytes
enting the TLX-binding site (AAGTCA) that lies ~80 bp upstream of Pax2 start site was
7 and SHH. (B) EMSA performed in which in vitro translated TLX protein was incubated
extracts from untreated astrocytes were incubated with biotinylated oligo (lane 3), or
esence of TLX antibody (lane 4). Lane 4 shows supershift in TLX band in the presence of
or TLX antibody (lane 1). (C) Quantitation of EMSA represented in A. Values above the
vehicle-treated cells. (D) Quantitative polymerase chain reaction (qPCR) of a chromatin
, BMP7, SHH, or BMP+SHH (n=6). TLX antibody was used to precipitate DNA/protein
ith Taqman qPCR. As a positive control, antibody against acetyl-Histone H3 was used to
sed for ampliﬁcation (ﬁrst bar). The values for the acetyl-histone H3were automatically
hown in D are normalized to GAPDH. Values for the rabbit IgG negative control were
t of Pax2 ampliﬁed in D as a result of growth factor treatment with the decrease in the
y incubating nuclear lysates with antibody against control β-tubulin (lane 1), pSMAD1
(c). (c). Lane 2 and 3 shows binding of TLX protein with pSMAD1 and GLI2 respectively.
D1 antibody. Lane 3 shows the presence of pSMAD1 signal in Co-Ip with GLI2. (c) Lane 2
tein levels in astrocytes treated overnight with BMP7, SHH and, BMP7 and SHH. Co-Ip
s depicted in F normalized to β-tubulin. Statistical signiﬁcance is indicated. (G) Avidin–
re binding at or near the TLX-binding site. Biotinylated oligonucleotide representing the
treated retinal astrocytes. No signal was present in samples incubated without labeled
lane 2).
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formation of glial scars following injury and in disease states
throughout the central nervous system (Hall and Miller, 2004). The
BMP-related SMADs interact withmembers of the ciliary neurotrophic
factor(CNTF)/leukemia inhibitory factor (Stayner et al. 1998) path-
ways, known as the signal transducers and transcription factors
(STATs), via the FRAP–STAT pathway (Rajan andMcKay,1998; Rajan et
al., 2003). The STATs and SMADs form a complex with the p300/CBP
proteins to increase transcription of the type III intermediate ﬁlament
protein GFAP (Yanagisawa et al., 2001). Together these two pathways
potentiate astrocyte induction (Nakashima et al., 1999). BMP7 has
been shown to be upregulated following spinal cord injury and to play
a neuroprotective role in the central nervous system (Cox et al., 2004;
Harvey et al., 2004; Setoguchi et al., 2001; Tsai et al., 2007). However,
we hypothesize, that while BMPs may play a role initially in
neuroprotection, they may also initiate reactive gliosis and/or
maintain glial scars that prevent regeneration of central nervous
system connections.
Future studies will be focused on determining the role of BMP7 and
SHH in both astrocyte development as well as the in glial scar
formation following injury and in disease states such as glaucoma,
diabetic retinopathy, and age-related macular degeneration.
Materials and methods
Materials used
Dulbecco's Modiﬁed Eagle's Medium (DMEM), cell dissociation
solution (Sigma; St. Louis, MO), FBS, penicillin/streptomycin, trypsin–
EDTA, Phenol:Choroform, DTT, ProLong antifademountingmediawith
DAPI (Invitrogen; Carlsbad, CA), INFγ, mouse N-terminus SHH
peptide, mouse BMP7 (R&D Systems; Minneapolis, MN), Hepes, L-
glutamine, NEAA (Cellgro; Herndon, VA), EC growth supplement,
protease inhibitor cocktail, RNase freewater, heparin (Sigma; St. Louis,
MO), PVDF membranes (Millipore; Bedford, MA), NaCl, Tris, NP-40,
sodium deoxycholate, EDTA, IGPEAL, glycerol, SDS, L-glutamine,
sodium pyruvate, CellBind™-treated dishes and ﬂasks (Fisher Scien-
tiﬁc; Hanover Park, IL), Roche buffer M, FuGene HD Transfection
Reagent (Roche; Indianapolis, IN), nuclear extraction kit, EMSA kit
(Panomics; Fremont, CA), ECL chemiluminescent substrate, protein G
plus beads (Pierce), chemiluminescence ﬁlms (Amersham Bio-
sciences, UK), DC assay kit (Bio-Rad; Hercules, CA), streptavidin
agarose resin (Thermo Scientiﬁc; Rockford, IL), cyclopamine (Calbio-
chem), SHH, BMP7, follistatin (R&D systems, Minneapolis, MN),
Luciferase Assay System, TNT Quick Coupled Transcription/Transla-
tion system (Promega, Madison, WI), pCMV-TLX neo6 expression
vector (Origene; Rockville, MD), mouse BMP7 and BMP7 function-
blocking serum (kind gift from Pamela J. Lein, Oregon Health and
Science University, Portland, Oregon).
Antibodies: rabbit anti-PAX2 (Covance; 1 μg/ml), rabbit anti-
phospho-PAX2 (Zymed; 2 μg/ml), rabbit anti-acetyl-Histone H3
(Millipore 17–615, 4 μg/ml ChIP), rabbit anti-SMAD1 (Zymed; 1 μg/
ml), rabbit anti-phospho-SMAD1 (Millipore; 1 μg/ml for westerns;
10 μg/ml for immunoﬂuorescence), rabbit anti-phospho-SMAD1
(Santa Cruz sc-12353; 4 μg/ml for ChIP), rabbit anti-SMAD2
(Zymed; 2 μg/ml), rabbit anti-TLX (Abcam ab30942; 0.4 μg/ml for
westerns, 4 μg/ml for ChIP), mouse anti-TLX (Abcam 10 μg/ml for
immunoﬂuorescence), rabbit anti-GLI2 (Abcam; 1 μg/ml for westerns,
10 mg/ml for immunoﬂuorescence), rabbit anti-GLI2 (Santa Cruz sc-
20290; 4 μg/ml ChIP); rabbit anti-GLI3 (Abcam; 10 μg/ml); rabbit
anti-GLI1 (Cell Signaling; 1:100), mouse anti-β-tubulin (Sigma; 1 μg/
ml), mouse anti-α tubulin (Sigma; 0.5 μg/ml), human anti-BMP7
(R&D systems; 2 μg/ml for westerns; 10 μg/ml for immunoﬂuores-
cence), rabbit anti-GFAP (Dako; 1:1000 for immunoﬂuorescence;
2 μg/ml for FACs); mouse anti-NG2 chondroitin sulfate proteoglycans
(Fisher Scientiﬁc; 2 μg/ml); ECL anti-rabbit HRP (1:5000; GEHealthcare, UK), anti-rabbit HRP for CO-IP (1:20,000; e Bioscience,
San Diego, CA), donkey anti-goat IgG conjugated to alexa-ﬂuor 594
(Molecular Probes Invitrogen, 1:1000); goat anti-mouse IgG con-
jugated to alexa-ﬂuor 594 (Molecular Probes Invitrogen, 1:1000), and
goat anti-rabbit IgG conjugated to alexa-ﬂuor 594 (Molecular Probes
Invitrogen, 1:1000).
Experimental animals
All animal experimentation described in this study was conducted
in accordance with accepted standards of humane animal care, the
NIH guidelines for the care and use of experimental animals, and
protocols approved by the institutional animal care and use
committees for Indiana University School of Medicine and University
of Wisconsin. Wild-type C3H mice and immorto-mice were housed
under pathogen-free conditions in controlled light cycle and tem-
peratures, and provided tap water and commercial mouse chow ad
libidum. Mating pairs were monitored daily for vaginal plugs.
Cell culture and gene regulation assays
Retinal astrocyteswere isolated from “immorto”mice back-crossed
to C57BL/6J and grown as previously described (Scheef et al., 2005)
andwere grown on CellBind™-treated dishes and ﬂasks. For luciferase
assays, a luciferase reporter gene containing 900 bp upstream of the
start site of the mouse Pax2 promoter (including the TLX-binding site)
was constructed in the pGL4.14 vector (Promega). Astrocytes were
cultured in 6×35 mm dishes. 5×105 astrocytes were transiently co-
transfected using Fugene HD transfection reagent with 300 ng of
reporter plasmid and 200 ng of expression vector. Parallel control
samples were co-transfected with equal amounts of empty vectors
(n=6 for each condition). After 24 h of transfection, cells were treated
with BMP7, SHH and, BMP7 and SHH. 24 h later, cells were lysed and
luciferase activity was measured using Beckman Coulter LD400 plate
reader/luminometer (Beckman Coulter, Fullerton, CA). Total protein
concentration was determined using Bio-Rad DC assay and luciferase
activities were normalized to protein concentration. Each experiment
was repeated at least three times (n=4+).
SDS-PAGE and western analysis
Astrocytes were seeded in 10mm culture dishes at a concentration
of 5×105 cells/ml. They were treated with BMP7 (200 ng/ml), SHH
(200 ng/ml) either alone or in combination. After 12–16 h of
treatment, cells were lysed by adding lysis buffer (50 mM Tris pH
7.4, 1% NP-40, 0.25% sodium deoxycholate, 150 mM sodium chloride,
1 mM EDTA, supplemented with 1 μg/ml protease inhibitors) for
30 min on ice. Cell lysates were centrifuged at 14,000 rpm for 15 min
at 4 °C and supernatant was collected. Total protein concentrationwas
determined using DC-Assay (Bio-Rad). Proteins were transferred to
PVDF membranes overnight at 4 °C and immunoblotted as described
in Nofziger et al. (2005). Densitometry of the blots was performed
using ImageJ 1.34 s software. Western data values for treated samples
were compared with vehicle samples using one-tailed Student's t-
test. Differences were considered signiﬁcant when p≤0.06. For total
PAX2 protein densitometric analysis, the PAX2 dimers were totaled
together because previous reports have shown no difference in the
ability of the two alternatively spliced products to bind to DNA and
activate expression (Phelps and Dressler, 1996).
Nuclear extract preparation
Nuclear extracts were prepared from wild type retinal astrocytes
using a nuclear extraction kit according to the manufacturer's
instructions (Panomics, Fremont, CA). Cells were grown to 90%
conﬂuence andwashedwith PBS. Buffer Aworking reagent containing
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inhibitor cocktail was added to the culture ﬂasks, kept on ice bucket
and incubated for 10 min on rocking platform. Cells were removed
using a sterile scraper and transferred to 1.5 ml microfuge tube and
centrifuged at 14,000 rpm for 3 min at 4 °C. To the pellet, Buffer B
working solution containing Buffer B (supplied with the kit), DTT and
protease inhibitor cocktail was added. Tubes were vortexed and
incubated horizontally on an ice bucket which was then transferred to
a rocking platform for 2 h. Sampleswere centrifuged and supernatants
were transferred to a fresh microfuge tube. Nuclear extracts were
stored at −80 °C until analyzed.
Electrophoretic mobility shift assay (EMSA) and in vitro translation
Mobility shift assays were performed using EMSA kits (Panomics)
according to the manufacturer's instructions with the following
additions or changes. Probes used for EMSA analysis were as follows:
anti-sense probe (5′–3′): AGCTTTGTCTGACAAGTCATCCATCTAGCT;
sense probe (5′–3′): AGCTAGATGGATGACTTGTCAGACAAAGCT. 4 μg
nuclear extract was incubated with 5× binding buffer, Poly d (I–C) for
5 min at room temperature before adding 1 μl of biotin-labeled Pax2
probe (prepared by annealing sense and biotin-labeled antisense
oligos by boiling 100 ng/μl of each oligo with 10× Roche buffer M for
5 min and kept at room temperature overnight). In vitro translations
were performed as in Pfäfﬂe et al. (2007).
Avidin–biotin conjugated DNA binding assay (ABCD)
The ABCD assay was performed as in Glass et al. (1987). Brieﬂy,
sense and biotin-labeled antisense oligos were ﬁrst annealed by
boiling 100 pmol/μl of each oligo with 10× Roche buffer M for 5 min
and kept at room temperature overnight. 10 μl of the total sample was
used for each reaction. 500 μg total proteins from astrocytes were
mixed with 100 μl of protease inhibitor cocktail, 10 μl of probe and
DNA pull down buffer pH 7.5 (containing 25 mM HEPES, 15 mM NaCl,
0.5 mM DTT, 0.5% IGEPAL, 0.1 mM EDTA and 10% glycerol) was added
to make total volume to 1 ml in 1.5 ml microfuge tubes. The solution
was incubated on rocker shaker at 4 °C overnight. 40 μl of 50%
streptavidin–agarose resin was added and was incubated for 6 h at
4 °C on rocker shaker. Tubes were centrifuged at 12,000 rpm for 2 min
and the pellet was thenwashed ﬁve times with DNA pull down buffer.
1× SDS-PAGE loading buffer was added to the pellet and boiled for
5 min. The samples were stored at −20 °C until further analyzed by
western blotting.
Co-immunoprecipitation
Co-immunoprecipitation was performed using the universal
magnetic Co-IP kit from Active Motif with minor modiﬁcations to
the manufacturer's instructions. Brieﬂy, nuclei were isolated from
cells using enzymatic digestion. Three hundredmicrograms of nuclear
protein extract was incubated with 5 μg of antibody speciﬁc for b-
tubulin, pSMAD1, or GLI2 overnight at 4 °C on a rotator. Following
incubation with antibody, lysates were incubated with magnetic
protein G beads for 3–4 h at 4 °C on a rotator. After washing beads 6
times in ice cold wash buffer, beads were suspended in 2× reducing
loading buffer (130 mm Tris pH6.8, 4% SDS, 0.02% bromophenol blue,
20% glycerol, 100mmDTT), vortexed tomix and stored at−80 °C until
western blotting was performed. Prior to loading, beads were boiled
for 10 min, spun, and the elute was subjected to SDS-PAGE. Following
transfer, blots were immunoblotted as in western analysis section.
Immunoﬂuorescence
Prior to immunohistochemistry, antigen retrieval was performed
by placing sections in 10 mM sodium citrate pH 6.0 at 65 °C andheating in a microwave on high for 20 min. Sections were then
allowed to come to room temperature prior to proceeding with the
immunoﬂuorescence protocol. Immunoﬂuorescence on sections was
performed as described in Wilson et al. (2007), with the exception
that slides were mounted using ProLong Gold with DAPI. Immuno-
cytochemistry was performed as described in Belecky-Adams et al.
(1996). Antibodies were used at the following dilutions: Pax2, 1:200;
TLX, 10 μg/ml; GLI1, 1:100, Gli2, 10 μg/ml, Gli3, 10 μg/ml, SHH, 10 μg/
ml, BMP7, 10 μg/ml, pSMAD1, 10 μg/ml.
FACScan analysis
FACS analysis was performed as described in Scheef et al., 2005.
Brieﬂy, cells were rinsed with phosphate buffered saline (PBS) with
0.4% EDTA. Cells were incubated with 2ml of dissociation solution and
rinsed from the plates with 5 ml of DMEM containing 10% fetal bovine
serum. Cells were spun, washed once one with tris-buffered saline
(TBS), resuspended in 0.5 ml of TBS with 1% goat serum, incubated for
20 min at 4 °C, incubated with 0.5 ml of rabbit anti-GFAP (2 μg/ml) or
rabbit anti-NG2 (2 μg/ml) for 30 min at 4 °C. FACS of labeled cells was
compared to samples incubated with control IgG in place of primary
antibodies.
Chromatin immunoprecipitation and quantitative PCR
Cells were rinsed with cold PBS, removed from dish with cell
scraper, and crosslinking carried out in a ﬁnal concentration of 1%
formaldehyde for 15 min on ice. Cells were subsequently incubated
with glycine to stop the crosslinking and were washed twice by
spinning at 4500 rpm for 7 min and rinsing the pellet in PBS
containing 1× protease inhibitor mix (Roche) and 0.1 mM PMSF at
4 °C. Following rinses, pellets were resuspended in ChIP dilution
buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris–HCl
pH8.1,167mMNaCl with 1× protease inhibitor mix and 0.1mMPMSF)
and stored at −80 °C. Upon thaw, cells were spun at 6000 rpm for
5 min and pellets resuspended in 200 ml of SDS lysis buffer (1% SDS,
10 mM EDTA, 50 mM Tris–HCl, pH8.1 with 1× protease inhibitor mix
and 0.1 mM PMSF) and incubated on ice for 10 min. The mixture was
sonicated for 3–4 sets of 10-second pulses using a Cole Palmer, High
Intensity Ultrasonic Processor/Sonicator, 50-watt model (with 2 mm
tip) set to 30% ofmaximum power. Debris was removed by spinning at
13,000 rpm for 10 min at 4 °C, supernatant transferred to a fresh tube
and 1.8 ml of ChIP dilution buffer added. Two hundred microliters of
sample was saved as an input control. For immunoprecipitation,
antibody was added at a ﬁnal concentration of 2 μg/ml and rotated
overnight at 4 °C. After overnight incubation, samples were incubated
with 60ml of protein A agarose, rotated for 1 h at 4 °C, and centrifuged
at 1000 rpm for 1 min at 4 °C. Beads were washed at room
temperature for 5 min on a rocker once in 1.0 ml of low salt wash
buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris–HCl, pH8.1,
150 mMNaCl), four times in 1.0 ml high salt wash buffer (0.1% SDS, 1%
Triton X-100, 2 mM EDTA, 20 mM Tris–HCl, pH8.1, 500 mM NaCl),
once in LiCl wash buffer (0.25M LiCl,1% NP-40,1% deoxycholate,1mM
EDTA, 10 mM Tris–HCl, pH8.1) and twice in TE. Samples were
incubated in 250 μl of freshly prepared elution buffer (1% SDS, 0.1 M
NaHCO3), incubated at room temp. for 15 min, beads spun out and
supernatant transferred to a fresh tube. Elution was repeated with
beads once more and eluates were combined. The sample and input
control were incubated with 20 μl of 5.0 M NaCl for 4 h at 65 °C, then
incubated in 20 μg of proteinase K. Samples were treated with phenol
chloroform and ethanol precipitated. Pelletswere resuspended in 50 μl
of TE and stored at−20 °C until qPCR performed. qPCRwas performed
using Taqman PCR Reagent kit and Applied Biosystems-7500 Real time
PCR system according to the manufacturer's instructions. Primer
Express 3.0 by Applied Biosystems was used to design Primers and
Probes. Oligonucleotide Probe had 5′ FAM and 3′ TAMRA reporter and
442 R. Sehgal et al. / Developmental Biology 332 (2009) 429–443quencher dyes respectively. GAPDH (used as endogenous control) and
Pax2 primers used were: GAPDH Forward Primer; 5′-GAAGGT-
GAAGGTCGGAGTC-3′, GAPDHReverse Primer; 5′-GAAGATGGTGATGG-
GATTTC-3′, GAPDH Probe FAM-CAAGCTTCCCGTTCTCAGCC-TAMRA,
PAX2 Forward Primer; 5′-CGGCGCTGGCGAATC-3′, PAX2 Reverse
Primer; 5′-CGGGAGATGGATGACTTGTCA-3′ Pax2 Probe; FAM-
AGAGTGGTGGAATCTA-TAMRA. Each reaction was performed in tripli-
cates and each experiment was performed at least 3 times. The data
was expressed as Log10 fold increase (mean±SD) above control.Acknowledgments
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